303 related articles for article (PubMed ID: 20494267)
1. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder.
Thurstone C; Riggs PD; Salomonsen-Sautel S; Mikulich-Gilbertson SK
J Am Acad Child Adolesc Psychiatry; 2010 Jun; 49(6):573-82. PubMed ID: 20494267
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.
Geller D; Donnelly C; Lopez F; Rubin R; Newcorn J; Sutton V; Bakken R; Paczkowski M; Kelsey D; Sumner C
J Am Acad Child Adolesc Psychiatry; 2007 Sep; 46(9):1119-1127. PubMed ID: 17712235
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
[TBL] [Abstract][Full Text] [Related]
7. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.
Martenyi F; Zavadenko NN; Jarkova NB; Yarosh AA; Soldatenkova VO; Bardenstein LM; Kozlova IA; Neznanov NG; Maslova OI; Petrukhin AS; Sukchotina NK; Zykov VP
Eur Child Adolesc Psychiatry; 2010 Jan; 19(1):57-66. PubMed ID: 19568826
[TBL] [Abstract][Full Text] [Related]
12. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.
Biederman J; Spencer TJ; Newcorn JH; Gao H; Milton DR; Feldman PD; Witte MM
Psychopharmacology (Berl); 2007 Jan; 190(1):31-41. PubMed ID: 17093981
[TBL] [Abstract][Full Text] [Related]
13. Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine.
Wilens TE; Adler LA; Tanaka Y; Xiao F; D'Souza DN; Gutkin SW; Upadhyaya HP
Curr Med Res Opin; 2011 Dec; 27(12):2309-20. PubMed ID: 22029549
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Heiligenstein JH; Faries DE; Galil N; Dittmann R; Emslie GJ; Kratochvil CJ; Laws HF; Schuh KJ;
Pediatrics; 2002 Dec; 110(6):e75. PubMed ID: 12456942
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.
Tsang TW; Kohn MR; Hermens DF; Clarke SD; Clark CR; Efron D; Cranswick N; Lamb C; Williams LM
Trials; 2011 Mar; 12():77. PubMed ID: 21396130
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
17. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
18. Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial.
Trzepacz PT; Spencer TJ; Zhang S; Bangs ME; Witte MM; Desaiah D
Curr Med Res Opin; 2011; 27 Suppl 2():45-52. PubMed ID: 21973230
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder.
McRae-Clark AL; Carter RE; Killeen TK; Carpenter MJ; White KG; Brady KT
Am J Addict; 2010; 19(6):481-9. PubMed ID: 20958842
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]